Cytomegalovirus Infections
📧 Sign up to get email alerts when something new happens for Cytomegalovirus Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated safety and immune response across different doses of a cytomegalovirus vaccine in healthy adults and ha…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
A completed clinical trial evaluating real-world monitoring of anti-CMV therapies in hematopoietic stem cell transplant recipients.
-
EMA approval · 2025-12-12EMA Authorised: Prevymis (Letermovir) — Merck Sharp & Dohme B.V.
The EMA authorised Prevymis (letermovir) from Merck Sharp & Dohme B.V. for cytomegalovirus infections. It carries an orphan designation.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) [Phase 2]
Phase 2 trial assessing safety and immunogenicity of the MVA-based CMV vaccine Triplex has completed.
-
CLINICAL_TRIALS research · 2025-10-22Clinical Trial Update: T Cell Therapy of Opportunistic Cytomegalovirus Infection [EARLY_Phase 1]
This early-phase clinical trial is evaluating T-cell therapy for opportunistic Cytomegalovirus infection in hematopoietic stem cell transpla…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus. [Phase 4]
Phase 4 trial in high-risk kidney transplant recipients evaluating CMV prevention strategies: tacrolimus-based regimens with anticipatory th…
-
CLINICAL_TRIALS other · 2025-08-05Clinical Trial Update: TETRAVI Expanded Access Program
This is an update on the TETRAVI Expanded Access Program sponsored by Baylor College of Medicine, covering viral infections including Epstei…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections [Phase 3]
Phase 3 clinical trial evaluating multivirus-specific T-cell transfer after stem cell transplantation to treat or prevent AdV, CMV, and EBV …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis [Phase 4]
Phase 4 trial of topical 2% ganciclovir eye drops for CMV anterior uveitis and endotheliitis has completed.
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis [NA]
The clinical trial is recruiting to evaluate whether the QuantiFERON-CMV diagnostic test can predict cytomegalovirus reactivation in patient…
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT) [NA]
Clinical trial update for the QUANTIFOT study (NCT06341543) evaluating QuantiFERON-CMV to identify the need for CMV treatment after solid or…
-
CLINICAL_TRIALS research · 2024-07-26Clinical Trial Update: Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
The TransmIT clinical trial, sponsored by the University of Massachusetts Worcester, is investigating CMV transmission and immune tracking a…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant [Phase 2, Phase 3]
Clinical trial update reporting completed results for Posoleucel (ALVR105) studied to prevent multiple viral infections after allogeneic hem…
-
CLINICAL_TRIALS withdrawal · 2024-02-28Clinical Trial Update: Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response [Phase 4]
A Phase 4 clinical trial involving mTOR inhibitors and CMV-specific immune response in kidney transplantation has been withdrawn.
-
FDA approval · 2023-11-29FDA Approved: FOSCARNET SODIUM — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved the original application for Foscarnet Sodium, a generic antiviral intended for CMV and acyclovir-resistant HSV infections.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. [Phase 3]
Phase 3 clinical trial evaluating reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients has compl…
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: CMV-CTL for the Treatment of CMV Infection After HSCT [Phase 4]
Phase 4 clinical trial update for CMV-CTL as a treatment for cytomegalovirus infection after hematopoietic stem cell transplantation has com…
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection [Phase 2]
A Phase 2 clinical trial update for letermovir in refractory or resistant Cytomegalovirus infection has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation [Phase 2]
Phase 2 trial comparing valganciclovir to valacyclovir for viral prophylaxis in kidney transplantation; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) [Phase 1]
Phase 1 trial update on safety and immunogenicity of CMV vaccine V160 in healthy Japanese men completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-10Clinical Trial Update: V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002) [Phase 2]
Phase 2 trial update for V160 regimens in CMV-seronegative healthy females; results completed and posted.
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [Phase 3]
Phase 3 trial investigating valganciclovir to prevent CMV organ damage in people with HIV has completed.
-
CLINICAL_TRIALS withdrawal · 2020-11-10Clinical Trial Update: Inflammation and Co-Infections in D²EFT [Phase 4]
A Phase 4 trial examining inflammation and co-infections in HIV/AIDS with multiple herpesvirus-related infections has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-05-19Clinical Trial Update: Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection
A completed clinical trial evaluating PK/PD of ganciclovir in premature infants treated for CMV infection; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults [Phase 1]
Phase 1 study evaluating safety, tolerability, and immunogenicity of a human cytomegalovirus vaccine in healthy adults completed with result…